PRP injection marketing: what clinics can claim

Platelet-rich plasma (PRP) injections are offered by orthopedic, sports medicine, pain, chiropractic, dermatology, hair restoration, med spa and integrative practices. The treatment is usually cash pay, which makes marketing central to it: a clinic that wants patients to pay out of pocket has to explain what it offers and why. That is also where clinics get into trouble, because PRP sits in a gap between FDA’s rules for blood products, devices and cell-based products, and because the strongest-sounding claims are the ones least likely to be backed by the kind of evidence the FTC expects.

This guide covers how the federal rules treat PRP, what the FTC Act requires of PRP advertising, how testimonials and before-and-after content fit in, and what Google Ads allows. Our guide to stem cell clinic advertising covers regenerative treatments that are HCT/Ps, and our guide to integrative medicine marketing claims covers health claims more broadly. For the specialty side, see sports medicine practice marketing. PRP offered with microneedling is covered in our guide to microneedling marketing. For cartilage regrowth claims, see knee osteoarthritis clinic marketing.

This is general information, not legal or medical advice, and it says nothing about whether PRP works for any condition. Sources cited were checked on November 1, 2026: 21 CFR 1271.3, 1271.10, 1271.15, 606.3 and 807.97, and 16 CFR 255.2, 465.2 and 1.98, in the eCFR version up to date as of October 29, 2026; 15 USC 45, 52 and 55 in the Cornell LII text of the U.S. Code; the Google Ads policy Speculative and experimental medical treatment, cell therapies, and gene therapies (support.google.com answer 15596627); and the FTC Health Products Compliance Guidance (December 2022, read October 28, 2026). We did not read FDA warning letters, FDA device clearance files, FTC cases about PRP or state laws for this guide.

The short version

The HCT/P rules are not the place to start. 21 CFR 1271.3(d)(2) excludes whole blood, blood components and blood derivative products subject to listing under parts 607 and 207 from the HCT/P definition, and 21 CFR 606.3 defines a blood component as a part of human blood separated by physical or mechanical means. Borrowing stem cell exemption language for PRP is a mistake. None of this makes PRP marketing unregulated.
Never say “FDA-approved PRP”. A device used to prepare PRP may have been cleared through premarket notification, but 21 CFR 807.97 says a clearance does not denote official approval, and any representation that creates that impression is misleading.
Claims need evidence before they run. The FTC Act bars false advertisements for services and devices (15 USC 52), and the FTC expects health benefit claims to be backed by competent and reliable scientific evidence, generally randomized, controlled human trials (FTC Health Products Compliance Guidance, December 2022).
Testimonials carry the same burden. A patient story about a result is read as a claim that the treatment works, and as typical unless you disclose what patients generally get (16 CFR 255.2(a), (b)). Fake or misleading reviews are banned outright by 16 CFR 465.2.
Google Ads does not allow PRP promotion. Google lists platelet rich plasma therapies among the cell or gene therapies it does not allow ads to promote, except FDA licensed or approved therapies promoted by the license holder and ads that are exclusively educational or informational.

How the federal rules classify PRP

Blood components are outside the HCT/P definition. FDA’s tissue rules in 21 CFR part 1271 apply to human cells, tissues and cellular and tissue-based products (HCT/Ps), defined in 1271.3(d) as articles containing or consisting of human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient. The same paragraph then lists articles that are not HCT/Ps, and 1271.3(d)(2) names “whole blood or blood components or blood derivative products subject to listing under parts 607 and 207 of this chapter.” FDA’s blood regulations define a blood component as “a product containing a part of human blood separated by physical or mechanical means” (21 CFR 606.3).

This matters for marketing because PRP ads often borrow language from stem cell marketing, including the same-day, same-patient exception. That exception, 21 CFR 1271.15(b), applies to an establishment that removes HCT/Ps from an individual and implants them into the same individual during the same surgical procedure. It is a rule about HCT/Ps. Citing it in a PRP ad, or implying that PRP is “exempt from FDA”, says something the regulation does not say. The same goes for the criteria in 1271.10(a), such as minimal manipulation and homologous use, which decide whether an HCT/P is regulated solely under section 361 of the Public Health Service Act.

We did not read FDA guidance or warning letters on how FDA classifies a particular PRP preparation made at the point of care, and the regulations above do not settle every case. If your clinic adds anything to PRP, combines it with other products, or markets it for a use that a device maker does not label, ask a regulatory attorney before you advertise it.

The device is a device. The centrifuge kit or system used to prepare PRP is a medical device. When a device reaches the market through premarket notification (a 510(k)), FDA’s finding is that it is substantially equivalent to a device already on the market. 21 CFR 807.97 says that finding “does not in any way denote official approval of the device” and that “any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding.” A clearance also covers the device’s intended use as stated in its own submission, not every treatment a clinic offers with it. Our guide to medical device marketing claims covers cleared, approved and registered wording in more detail.

What the FTC Act requires of PRP ads

15 USC 52(a) makes it unlawful to disseminate a false advertisement likely to induce the purchase of food, drugs, devices, services or cosmetics, and 52(b) makes doing so an unfair or deceptive act under 15 USC 45. A PRP injection is a service, so a clinic’s ads, website, social posts and seminar slides are covered. 15 USC 55(a)(1) defines a false advertisement as one that is misleading in a material respect, and counts not only what the ad says or suggests by “statement, word, design, device, sound” but also its failure to reveal facts material to those representations.

The FTC’s Health Products Compliance Guidance (December 2022) explains how the agency applies that standard to health claims. Points that apply directly to PRP:

Health benefit claims need “competent and reliable scientific evidence”, and the guidance says that as a general matter this will need to be randomized, controlled human clinical testing.
The research has to match what you sell. In one of its examples, an in vitro study that used a different formulation, with a higher concentration than the marketed product, is part of why the substantiation falls short. PRP preparations vary from system to system and protocol to protocol, so a study on one preparation, for one condition, does not carry over to every PRP service.
The totality of the evidence counts. If a stronger body of research runs against a claimed effect, even a qualified claim is likely to be deceptive, and continuing to promote one favorable small study can be deceptive.
If an ad would be misleading without key qualifying information, that information must be disclosed, including significant limitations on the advertised benefit.

In practice, the highest-risk PRP claims are the ones that promise outcomes: “heals torn tendons”, “regrows cartilage”, “avoid surgery”, “permanent hair regrowth”, “reverses aging”, or a success percentage with no study behind it. Claims that describe the service without promising results are lower risk: what PRP is, how the sample is drawn and prepared, how long the visit takes, what the clinic charges, who performs it and what the clinic’s own process for deciding whether a patient is a candidate looks like. Our guide to “clinically proven” and “doctor recommended” claims covers establishment claims of that kind.

Testimonials, reviews and before-and-after photos

Patient stories are common in PRP marketing, and the FTC rules on them are specific. Under 16 CFR 255.2(a), an ad using consumer endorsements about a product’s performance is read as saying the product is effective for the purpose shown, so the advertiser needs the same substantiation it would need to make the claim directly, and “consumer endorsements themselves are not competent and reliable scientific evidence.” Under 255.2(b), a testimonial about a key attribute is likely read as representative of what people generally achieve; if you lack evidence that it is, the ad should clearly and conspicuously disclose the generally expected performance, and you need evidence for that too.

For PRP, that means a knee patient’s story about avoiding surgery, or a hair patient’s dramatic before-and-after, makes a claim about the treatment, not only about that patient. “Results may vary” does not tell anyone what results to expect. Before-and-after photos also raise consent questions under HIPAA when they come from your own patients; see our guide to patient testimonials and before-and-after photos.

Reviews are covered by a separate rule. 16 CFR 465.2(a) makes it an unfair or deceptive practice for a business to write, create or sell a consumer review or testimonial that materially misrepresents that the reviewer exists, that the reviewer used the service, or the reviewer’s experience. Section 465.2(b) covers buying such reviews or disseminating testimonials the business knew or should have known were misleading in those ways. Part 465 is a trade regulation rule, so the FTC can seek civil penalties for knowing violations under 15 USC 45(m)(1)(A). The statute sets not more than $10,000 per violation; 16 CFR 1.98(d) lists the inflation-adjusted maximum as $53,088.

Google Ads and other ad platforms

Google’s policy on speculative and experimental medical treatment, cell therapies, and gene therapies does not allow the promotion of cell or gene therapies, and its non-exhaustive examples include stem cell therapy, cellular (non-stem) therapy, gene therapy and similar regenerative medicine, and “platelet rich plasma, also referred to as PRP therapies.” In the United States, Google allows promotion of FDA licensed or approved cell or gene therapies by the entity that holds the license or approval, and it allows ads that are exclusively educational or informational in nature, with academic papers and medical conference tickets as examples. A clinic ad for its own PRP service fits neither exception.

That has two practical results. First, a search campaign built around PRP keywords and PRP landing pages runs into this policy. Google states that violations of it will not lead to immediate account suspension without prior warning, and that it issues a warning at least 7 days before suspending an account. Second, a clinic that offers PRP alongside other services should build campaigns and landing pages for the services Google does allow, and keep PRP on organic pages. Our guide to why healthcare ads get disapproved covers appeals and fixes. We did not read Meta, Microsoft or TikTok policy for PRP for this guide; check each platform’s current health policy before you run ads there.

Pricing and cash-pay offers

Because PRP is usually self-pay, price is part of the pitch. Advertised prices, package deals, series discounts and “was/now” offers are claims too, and they need to match what patients actually pay. Our guides to advertising cash prices and was/now sale price claims cover those rules, and our guide to good faith estimates for self-pay patients covers the estimate a provider owes uninsured and self-pay patients who schedule or ask for one. Do not say or imply that insurance covers PRP unless you have checked with the payer for the specific use.

An illustration

This is a made-up example, not a client. A sports medicine clinic adds PRP and buys a marketing package from its kit supplier. The package includes a landing page headed “FDA-approved PRP: heal without surgery”, three patient video testimonials from other clinics, a “92% success rate” banner with no source, a Google Ads campaign on PRP keywords, and copy saying PRP is “exempt from FDA because it is your own blood.”

The fix: the clinic removes “FDA-approved” (21 CFR 807.97) and the exemption claim, which borrows a rule written for HCT/Ps (1271.15(b)). The success rate goes, because the clinic cannot show the study behind it or that it applies to its own preparation and patients. The supplier testimonials go, because they are not the clinic’s patients and could misrepresent the reviewers’ experience with this clinic (16 CFR 465.2). The new page explains what PRP is, how the clinic prepares it, which conditions its physicians evaluate patients for, what the evidence does and does not show with links to the studies the physicians rely on, the price, and how to book a consultation. The paid campaign moves to the clinic’s other sports medicine services, and the PRP page is promoted through organic search and email to existing patients who opted in.

Checklist

No “FDA-approved”, “FDA-cleared treatment” or “FDA-exempt” wording for PRP (21 CFR 807.97; 1271.3(d)(2)).
No use of the HCT/P same-procedure exception (1271.15(b)) or section 361 criteria (1271.10(a)) to describe PRP.
Every outcome claim tied to studies on a comparable preparation and condition, kept on file before the ad runs (FTC Health Products Compliance Guidance).
No success rates, percentages or “avoid surgery” promises without that evidence.
Testimonials only from your own patients, with authorization, and with a clear statement of generally expected results if the story is not typical (16 CFR 255.2).
No written, bought or supplier-supplied reviews (16 CFR 465.2).
Material limitations disclosed: number of sessions, time to any effect, conditions where evidence is limited, cost (15 USC 55(a)(1)).
PRP kept out of Google Ads campaigns and ad landing pages unless the content is exclusively educational.
Prices and package terms match what patients pay; no insurance coverage implied.
Supplier marketing kits reviewed line by line before anything is published.

How we help

We write and build service pages, landing pages and campaigns for cash-pay services with the claims checked against the sources above: website design, healthcare SEO for the organic pages PRP depends on, and lead generation through channels that allow the service. We do not give medical opinions on PRP or legal opinions on FDA status, and we are not a law firm. Related guides: orthopedic practice marketing, hair restoration clinic marketing and pain management clinic marketing.

Can we say PRP is FDA-approved?

No. A device used to prepare PRP may be cleared through premarket notification, but 21 CFR 807.97 says that does not denote official approval, and any representation that creates an impression of official approval because of the clearance is misleading.

Is PRP regulated like stem cells?

21 CFR 1271.3(d)(2) excludes whole blood, blood components and blood derivative products subject to listing under parts 607 and 207 from the HCT/P definition, so the HCT/P rules are not the starting point for PRP, though we did not read FDA material on every point-of-care preparation. The FTC Act still applies to how you advertise it (15 USC 52).

Can we run Google Ads for PRP?

Google’s policy lists platelet rich plasma therapies among the cell or gene therapies it does not allow ads to promote. The exceptions are FDA licensed or approved therapies promoted by the license holder in the United States, and ads that are exclusively educational or informational.

Can we share patient success stories?

Yes, with the patient’s authorization, but the FTC reads a performance testimonial as a claim that the treatment works and, for key attributes, as representative of typical results. You need evidence for both, or a clear disclosure of generally expected results (16 CFR 255.2).

Can we use testimonials our PRP kit supplier provides?

Testimonials from other clinics’ patients are not reviews of your service. 16 CFR 465.2 bars disseminating testimonials a business knew or should have known misrepresent the testimonialist’s experience with the business, product or service.

What are the penalties for fake reviews?

Part 465 is a trade regulation rule, so knowing violations can bring civil penalties under 15 USC 45(m)(1)(A): not more than $10,000 per violation in the statute, adjusted to $53,088 in 16 CFR 1.98(d).

Sources

More in Cash-pay, aesthetic and wellness care

PRP injection marketing: what clinics can claim about platelet-rich plasma